THE MULTIDRUG RESISTANT PHENOTYPE IN CLINICAL-PRACTICE - EVALUATION OF CROSS RESISTANCE TO IFOSFAMIDE AND MESNA AFTER VP16-213, DOXORUBICIN AND VINCRISTINE (VPAV) FOR SMALL CELL LUNG-CANCER

被引：37

作者：

CANTWELL, BMJ

BOZZINO, JM

CORRIS, P

HARRIS, AL

机构：

[1] UNIV NEWCASTLE UPON TYNE,NEWCASTLE GEN HOSP,CTR REG RADIOTHERAPY,DEPT CLIN ONCOL,NEWCASTLE TYNE NE4 6BE,ENGLAND

[2] FREEMAN HOSP,DEPT RESP MED,NEWCASTLE TYNE NE7 7DN,ENGLAND

来源：

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1988年 / 24卷 / 02期

关键词：

D O I：

10.1016/0277-5379(88)90242-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：123 / 129

页数：7

共 37 条

[1]

[Anonymous], 1979, WHO HDB REPORTING RE

[2]

TREATMENT OF IFOSFAMIDE-INDUCED UROTHELIAL TOXICITY BY ORAL-ADMINISTRATION OF SODIUM 2-MERCAPTOETHANE SULFONATE (MESNA) TO PATIENTS WITH INOPERABLE LUNG-CANCER [J].

ARAUJO, CE ;

TESSLER, J .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :195-201

[3]

COMBINED MODALITY TREATMENT OF SHORT DURATION IN SMALL CELL LUNG-CANCER [J].

BAKKER, W ;

NIJHUISHEDDES, JMA ;

VANOOSTEROM, AT ;

NOORDIJK, EM ;

HERMANS, J ;

DIJKMAN, JH .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (08) :1033-1037

[4]

DETECTION OF P-GLYCOPROTEIN IN OVARIAN-CANCER - A MOLECULAR MARKER ASSOCIATED WITH MULTIDRUG RESISTANCE [J].

BELL, DR ;

GERLACH, JH ;

KARTNER, N ;

BUICK, RN ;

LING, V .

JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (03) :311-315

[5]

BRYANT BM, 1980, LANCET, V2, P657

[6]

BURKERT H, 1982, SEMIN ONCOL, V9, P28

[7]

FALSE-POSITIVE KETONURIA DURING IFOSFAMIDE AND MESNA THERAPY [J].

CANTWELL, BMJ ;

POOLEY, J ;

HARRIS, AL .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (02) :229-230

[8]

COHEN MH, 1979, CANCER TREAT REP, V63, P163

[9]

COHEN MH, 1983, CANCER TREAT REP, V67, P217

[10]

COOKSEY JA, 1979, EUR J CANCER, V13, P859

← 1 2 3 4 →